WALTHAM, Mass., May 2, 2025 - Spyre Therapeutics, Inc. $(SYRE)$, a clinical-stage biotechnology company, has announced the approval of stock options as an equity inducement for seven non-executive employees. The company's independent Compensation Committee of the Board of Directors has granted options to purchase a total of 64,400 shares under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan. Approved on May 1, 2025, the stock options have a 10-year term with an exercise price of $14.66, matching the closing price of Spyre's common stock on that date. The vesting schedule stipulates that one-fourth of the shares become exercisable on the first anniversary of the employee's start date, with the remainder vesting monthly over four years, contingent on continuous service with the company.